Acurx Pharmaceuticals Presents Ibezapolstat Efficacy Against CDI and Enterococcus Co-Cultures

Generated byAinvest NewsReviewed byRodder Shi

Monday, Sep 14, 2026 8:06 am ET1min read

ACXP--

Aime Summary

- Acurx PharmaceuticalsACXP-- presented ibezapolstat's (IBZ) potent bactericidal activity against C. difficile and Enterococcus at the 9th International C. difficile Symposium.

- The study demonstrated IBZ's superior efficacy in co-culture conditions, reducing toxin B expression and eradicating vancomycin-resistant bacterial overgrowth.

- IBZ has received FDA QIDP/Fast-Track and EMA SME designations, highlighting its potential as an innovative antibiotic candidate.

Acurx Pharmaceuticals presented a scientific poster at the 9th International C. difficile Symposium, highlighting the bactericidal activity of ibezapolstat (IBZ) against Clostridioides difficile and Enterococcus in standalone and co-culture environments. The study showed that IBZ maintained superior killing activity under co-culture conditions, including reducing C. difficile toxin B expression and eradicating vancomycin-resistant bacterial overgrowth. AcurxACXP-- has been granted FDA QIDP and Fast-Track Designation and SME designation by the EMA.

Ainvest News

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue